Pharmokinetics

#Analysis #Assay development optimisation & technology #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Pharmokinetics #Preclinical #RNA

Lean Six Sigma – Its application to drug discovery

Lean Six Sigma - Its application to drug discovery By Clare Hammond and Charles J O'Donnell In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Microfluidics #PCR #Pharmokinetics #RNA #Screening #Sequencing #Stem cells

Microplate Mixing – Bioassay panacea or of unproven distraction?

Microplate Mixing - Bioassay panacea or of unproven distraction? By Dr John Comley Despite general awareness of the significance of microplate mixing, it is still a relatively low priority in most laboratories. Microplate mixing has largely been ignored as a serious problem, although potentially it could undermine the generation of… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Perspectives for ADMET Integration in the Discovery Process

Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Pathology #Pharmokinetics #RNA

Opportunities in Gastroenterology

Opportunities in Gastroenterology By Dirk Reyn Despite being one of the world's largest therapeutic areas and presenting huge burdens to healthcare and economies globally, many of the diseases of the gastrointestinal (GI) tract are not well understood and less than optimally treated. This article discusses that, given the large public… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Theranostics #Therapeutics #Toxicology

Industry Strategies on Theranostics: Need for structural alignment

Industry Strategies on Theranostics: Need for structural alignment Dr Rutger O. van Merkerk and Dr Wouter P.C. Boon Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information. Companies that adhere to this… Read More

#Archive

#Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Target validation #Therapeutics #Toxicology

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More

#Archive

#ADME / Tox #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Imaging #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Positron Emission Tomography (PET) – Shining a light on human disease

By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More

#Archive

Genome editing concept
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Metabolomics #Molecular medicine #Patent Law #Pharmacogenomics #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Theranostics #Toxicology

The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity

The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Regulatory #RNA #Stem cells #System biology #Therapeutics #Toxicology

Monoclonals – The billion dollar molecules of the future

Monoclonals - The billion dollar molecules of the future By Dr Martin Wiles and Patrik Andreassen In 1975, two British scientists thought of creating a mouse antibody that could be replicated or 'cloned' to produce identical copies. Identical copies with identical modes of action had the potential to be a… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Toxicology

Zebrafish: a versatile in vivo model for drug safety assessment

Zebrafish: a versatile in vivo model for drug safety assessment Dr Wendy Alderton and Dr St phane Berghmans Safety pharmacology has become an integral part of non-clinical safety assessment for new chemical entities in the past two decades (1). The relative novelty of this discipline has granted it the flexibility… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #PCR #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology

Kinase Inhibitor Screening – Latest technologies and techniques

Kinase Inhibitor Screening - Latest technologies and techniques By Dr Richard M. Eglen and Dr Roger Bossé Kinases have become a proven target class for new drugs and have created a thirst for the development of new technology platforms for inhibitor detection. We discuss some of the latest technologies and… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Organic chemistry #Patent Law #PCR #Pharmacology #Pharmokinetics #Preclinical #RNA #Screening #Toxicology

Medicinal Chemistry: Progress through innovation

Medicinal Chemistry: Progress through innovation By Dr Terry Hart Medicinal chemistry is a specialised science that has evolved to encompass a broad range of disciplines concerned with the identification, synthesis and development of drug-like compounds for therapeutic use. It needs a wide range of expertise, developed through years of training,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High throughput screening #Lead discovery #Medicinal chemistry #Patent Law #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Ion Channel Drug Targets: Unlocking the potential

Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cell culture #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Immunology #Lead discovery #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics

Immunogenicity of Therapeutic Proteins

Immunogenicity of Therapeutic Proteins By Dr Ivo Van Walle, Dr Ignace Lasters and Philippe Stas Therapeutic proteins enter the market in increasing numbers, and current observations confirm that most of these biopharmaceuticals are to a variable extent immunogenic. This may compromise the efficacy, safety as well as the target market… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microbiology #Microfluidics #Organic chemistry #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Current Biosensor Technologies in Drug Discovery

Current Biosensor Technologies in Drug Discovery By Dr Matthew A. Cooper Over the past two decades the benefits of biosensor analysis have begun to make an impact in the market, and systems are beginning to be used as mainstream research tools in many laboratories. Biosensors are devices that use biological… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Changing Dynamics in Dispense and Imaging Assays

Changing Dynamics in Dispense and Imaging Assays By Dr John Comley The prospects for a significant shift in dispense and imaging (D&I) assays towards a greater utilisation of calcium-mediated flash luminescence readouts appears to be finally under way. Driving this changing dynamic is the acceptance that assay sensitivity (better quality… Read More

#Archive